DMP.DE Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 apr 2024 @ 17:35):

Stats
Dagens volum	38 113.00
Gjennomsnittsvolum	20 397.00
Markedsverdi	1.69B
EPS	€0 ( 2024-03-27 )
Neste inntjeningsdato	( €0 ) 2024-05-13
Last Dividend	€1.050 ( 2023-06-15 )
Next Dividend	€0 ( N/A )
P/E	17.78
ATR14	€0.0750 (0.24%)

Volum Korrelasjon

Lang: -0.26 (neutral)

Kort: -0.96 (very strong negative)

Signal:(61.167) Neutral

Dermapharm Holding SE Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Dermapharm Holding SE Korrelasjon - Valuta/Råvare

0.37
( neutral )

0.28
( neutral )

0.00
( neutral )

0.28
( neutral )

-0.30
( neutral )

-0.49
( neutral )

Dermapharm Holding SE Økonomi

Annual	2022
Omsetning:	€1.02B
Bruttogevinst:	€660.83M (64.49 %)
EPS:	€2.49

FY	2022
Omsetning:	€1.02B
Bruttogevinst:	€660.83M (64.49 %)
EPS:	€2.49

FY	2021
Omsetning:	€942.91M
Bruttogevinst:	€620.69M (65.83 %)
EPS:	€3.89

FY	2020
Omsetning:	€793.83M
Bruttogevinst:	€463.48M (58.39 %)
EPS:	€1.590

Financial Reports:

No articles found.

Dermapharm Holding SE Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
€0 (N/A)	€0 (N/A)	€0 (N/A)	€1.050 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)	€0 (N/A)

Dermapharm Holding SE Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 7.09 - Increase likely (41.71%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	€0.770	2019-06-05
Last Dividend	€1.050	2023-06-15
Next Dividend	€0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	5	--
Total Paid Out	€5.67	--
Avg. Dividend % Per Year	0.00%	--
Score	3.23	--
Div. Sustainability Score	10.00
Div.Growth Potential Score	7.09
Div. Directional Score	8.93	--

Next Divdend (Est)
(2025-03-31)

€0.606 Estimate 3.09 %

Dividend Stability

0.25 Very Poor

Dividend Score

3.23

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Furthermore, its high Dividend Growth Potential Score (DGPS) signals potential dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for XETRA

Symbol	Title	Last dividend	Frequency	Yearly Dividend
NGLB.DE	Ex Dividend Knight	2023-08-17	Semi-Annually	0.00%
ABR.DE	Ex Dividend Knight	2023-08-30	Quarterly	0.00%
YCP.DE	Ex Dividend King	2023-09-27	Bi-Monthly	0.00%
G24.DE	Ex Dividend Junior	2023-06-23	Annually	0.00%
PND.F	Ex Dividend Knight	2023-09-01	Quarterly	0.00%
BAC.DE	Ex Dividend Knight	2023-10-09	Quarterly	0.00%
HXCK.DE	Ex Dividend Junior	2023-05-11	Sporadic	0.00%
SIX2.DE	Ex Dividend Junior	2023-05-24	Annually	0.00%
CMC.DE	Ex Dividend Knight	2023-10-05	Quarterly	0.00%
KTF.DE	Ex Dividend Knight	2023-06-29	Quarterly	0.00%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0821	1.500	8.36	10.00	[0 - 0.5]
returnOnAssetsTTM	0.0440	1.200	8.53	10.00	[0 - 0.3]
returnOnEquityTTM	0.174	1.500	9.17	10.00	[0.1 - 1]
payoutRatioTTM	0.595	-1.000	4.05	-4.05	[0 - 1]
currentRatioTTM	1.857	0.800	5.72	4.57	[1 - 3]
quickRatioTTM	0.798	0.800	-0.0114	-0.00913	[0.8 - 2.5]
cashRatioTTM	0.347	1.500	9.18	10.00	[0.2 - 2]
debtRatioTTM	0.508	-1.500	1.539	-2.31	[0 - 0.6]
interestCoverageTTM	4.32	1.000	9.51	9.51	[3 - 30]
operatingCashFlowPerShareTTM	5.18	2.00	8.27	10.00	[0 - 30]
freeCashFlowPerShareTTM	4.45	2.00	7.77	10.00	[0 - 20]
debtEquityRatioTTM	2.01	-1.500	1.968	-2.95	[0 - 2.5]
grossProfitMarginTTM	0.642	1.000	2.64	2.64	[0.2 - 0.8]
operatingProfitMarginTTM	0.192	1.000	8.15	8.15	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0.254	1.000	9.70	9.70	[0.2 - 2]
assetTurnoverTTM	0.536	0.800	9.76	7.81	[0.5 - 2]
Total Score				10.77

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	17.75	1.000	8.31	0	[1 - 100]
returnOnEquityTTM	0.174	2.50	9.47	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	4.45	2.00	8.52	10.00	[0 - 30]
dividendYielPercentageTTM	3.35	1.500	10.00	0	[0 - 0.4]
operatingCashFlowPerShareTTM	5.18	2.00	8.27	10.00	[0 - 30]
payoutRatioTTM	0.595	1.500	4.05	-4.05	[0 - 1]
pegRatioTTM	13.67	1.500	10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.241	1.000	6.48	0	[0.1 - 0.5]
Total Score				7.09

Dermapharm Holding SE

Dermapharm Holding SE, together with its subsidiaries, engages in the off-patent branded pharmaceuticals business in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription natural remedies, and other healthcare products. It also offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology primarily under the Dekristol, Dekristolvit, Allergovit, and Tromcardin brands. In addition, the company provides medical devices under the bite away and Herpotherm names; Momekort, a nasal spray used to treat allergy symptoms; and Azedil, a nasal spray or eye drop. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. It serves pharmaceutical wholesalers, pharmacies, hospitals, and health food stores. The company was founded in 1991 and is headquartered in Grünwald, Germany. Dermapharm Holding SE is a subsidiary of Themis Beteiligungs-Aktiengesellschaft.